



STOP-ACEi

CRF01 - RANDOMISATION NOTEPAD

Name of person that completed CRF, please print: This person must be listed on the STOP-ACEi delegation log.
Date CRF completed:	<input type="text" value="D"/> <input type="text" value="D"/> / <input type="text" value="M"/> <input type="text" value="M"/> <input type="text" value="M"/> / <input type="text" value="Y"/> <input type="text" value="Y"/> <input type="text" value="Y"/> <input type="text" value="Y"/>

Part A: Participant Details

Investigator:	Centre:
Date of Birth: <input type="text" value="D"/> <input type="text" value="D"/> / <input type="text" value="M"/> <input type="text" value="M"/> <input type="text" value="M"/> / <input type="text" value="Y"/> <input type="text" value="Y"/> <input type="text" value="Y"/> <input type="text" value="Y"/>	Sex: Female <input type="checkbox"/> Male <input type="checkbox"/>
First Name:	Surname:
NHS number: <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	
And for Scottish participants, CHI number: <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	
Participant ethnicity code (Please use coded list at the end of this document): <input type="text"/> <input type="text"/>	

Part B: Eligibility checklist

Eligibility must be assessed by medically qualified personnel. To be eligible, no shaded boxes can be ticked.

	No	Yes
Is the potential participant aged 18 years or over (male or female)?	<input type="checkbox"/>	<input type="checkbox"/>
Does the potential participant have stage 4 or 5 CKD? eGFR of <30 mL/min/1.73m ² confirmed using 4 variable MDRD equation.	<input type="checkbox"/>	<input type="checkbox"/>
Does the potential participant have progressive deterioration in renal function as confirmed by the spreadsheet tool provided? Progressive deterioration is defined as a fall in eGFR of >2mL/min/year over the previous 24 months. A minimum of 3 eGFR measurements from the last 24 months are required. One must be from within the last 3 months.	<input type="checkbox"/>	<input type="checkbox"/>
Has the potential participant been on treatment with an ACEi or ARB, or combination of both, for more than 6 months?	<input type="checkbox"/>	<input type="checkbox"/>
Is the potential participant currently on at least 25% of the maximum recommended daily dose of ACEi or ARB?	<input type="checkbox"/>	<input type="checkbox"/>
Has the potential participant had at least 3 months of specialist renal follow-up at the time of entry into the trial?	<input type="checkbox"/>	<input type="checkbox"/>
Is the potential participant's resting blood pressure lower than or equal to 160/90 mmHg when measured in accordance with British Hypertension Society guidelines? Clinic readings or home readings from within the last month or a 24 hour ambulatory blood pressure measurement within the last 3 months are acceptable.	<input type="checkbox"/>	<input type="checkbox"/>
Does the potential participant have a blood pressure of more than 160/90 mmHg or require 5 or more agents to control blood pressure?	<input type="checkbox"/>	<input type="checkbox"/>
Is the potential participant undergoing dialysis therapy?	<input type="checkbox"/>	<input type="checkbox"/>
Has the potential participant had a kidney transplant?	<input type="checkbox"/>	<input type="checkbox"/>
Does the potential participant have any condition which, in the opinion of the investigator, makes them unsuitable for trial entry due to prognosis or a terminal illness with a projected survival of less than 12 months?	<input type="checkbox"/>	<input type="checkbox"/>

	No	Yes
Does the potential participant have a history of myocardial infarction or stroke in the preceding 3 months?	<input type="checkbox"/>	<input type="checkbox"/>
Does the potential participant have an immune-mediated renal disease that requires disease-specific treatment?	<input type="checkbox"/>	<input type="checkbox"/>
Is the potential participant pregnant or breastfeeding?	<input type="checkbox"/>	<input type="checkbox"/>
Does the potential participant have a known drug or alcohol abuse problem?	<input type="checkbox"/>	<input type="checkbox"/>
Has the potential participant taken part in another interventional research study within the last 6 weeks?	<input type="checkbox"/>	<input type="checkbox"/>
Is the potential participant able to comply with the trial schedule and follow-up?	<input type="checkbox"/>	<input type="checkbox"/>
Is the potential participant able to provide informed consent?	<input type="checkbox"/>	<input type="checkbox"/>
Eligibility assessed by (name): Must be a clinician named on delegation log.		

Part C: Confirmation of eligibility

Progressive decline in renal function

To be eligible for the study, the participant must have progressive deterioration in renal function which is defined as a fall in eGFR of more than 2 mL/min/1.73m² per year. To confirm this, a minimum of 3 eGFR measurements from the last 24 months are required. At least one must be from within the last 3 months. Please record the creatinine readings used to determine eligibility here (please list measurements in chronological order, with the oldest listed first):

Creatinine 1:	<input type="text"/>	<input type="text"/>	<input type="text"/>	µmol/L	Date:	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
Creatinine 2:	<input type="text"/>	<input type="text"/>	<input type="text"/>	µmol/L	Date:	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
Creatinine 3:	<input type="text"/>	<input type="text"/>	<input type="text"/>	µmol/L	Date:	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
Creatinine 4:	<input type="text"/>	<input type="text"/>	<input type="text"/>	µmol/L	Date:	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
Creatinine 5:	<input type="text"/>	<input type="text"/>	<input type="text"/>	µmol/L	Date:	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
Creatinine 6:	<input type="text"/>	<input type="text"/>	<input type="text"/>	µmol/L	Date:	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

Stage 4 or 5 CKD

To be eligible for the study, the participant must have stage 4 or 5 CKD, that is an eGFR of less than 30 mL/min/1.73m² confirmed using the 4 variable MDRD equation. Please record the reading used to determine eligibility here:

eGFR:	<input type="text"/>	mL/min/1.73m ²	Date:	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
-------	----------------------	---------------------------	-------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------

Controlled blood pressure

To be eligible for the study, the participant must have controlled blood pressure of less than or equal to 160/90 mmHg. This can be determined from clinic readings or home readings from within the last month, or a 24 hour ambulatory blood pressure measurement within the last 3 months. Blood pressure should be measured according to current BHS guidelines. Please record the reading and method used to determine eligibility here:

Method:	Clinic reading <input type="checkbox"/>	Home reading <input type="checkbox"/>	24 hr ambulatory <input type="checkbox"/>									
BP:	<input type="text"/>	/	<input type="text"/>	mmHg	Date:	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

Part D: Minimisation variables

Urinary PCR or ACR by early morning spot urine

Please provide the most recent protein:creatinine ratio or albumin:creatinine ratio.

Urinary PCR:	<input type="text"/>	<input type="text"/>	<input type="text"/>	mg/mmol	Urinary ACR:	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	mg/mmol	
Diabetes												
Please select one option:												
Type 1 diabetic <input type="checkbox"/>				Type 2 diabetic <input type="checkbox"/>								
Non-diabetic <input type="checkbox"/>												
Type 2 diabetes includes non-insulin dependent diabetes and insulin-treated type 2 diabetes.												

Part E: Informed consent

If participant fulfils all the eligibility criteria, please proceed to informed consent.

Consent for main study	
Has the participant given informed consent for the main study?	No <input type="checkbox"/> Yes <input type="checkbox"/>
Version of informed consent form used:	<input type="checkbox"/> <input type="checkbox"/> . <input type="checkbox"/>
Optional consents	
Has the participant given consent for serum and urine samples to be taken, stored and used for future analysis of biomarkers both within this study and in future related studies?	No <input type="checkbox"/> Yes <input type="checkbox"/>
Has the participant consented to allow information held and maintained by The Health and Social Care Information Centre and current and future UK NHS bodies being used in the future to provide information about their long-term health status and health care, and for BCTU to hold their name, gender, date of birth and NHS number for this purpose?	No <input type="checkbox"/> Yes <input type="checkbox"/>

Part F: Randomisation

Thank you for completing the STOP-ACEi CRF01: Randomisation Notepad

STOP-ACEi Online Randomisation and Data Entry: <https://www.trials.bham.ac.uk/STOPACEi> (24hrs)
STOP-ACEi Telephone Randomisation: 0800 953 0274 (UK toll free), 9am to 5pm Mon-Fri.

STOP-ACEi Study Office, Birmingham Clinical Trials Unit, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT.

Tel: 0121 415 9130, Fax: 0121 415 9135, E-mail: STOPACEi@trials.bham.ac.uk

STOP-ACEi website: www.birmingham.ac.uk/STOPACEi

Date of Randomisation:	<input type="text"/> <input type="text"/> / <input type="text"/> <input type="text"/> / <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>
Arm participant randomised to:	Continue ACEi/ARBs <input type="checkbox"/> Discontinue ACEi/ARBs <input type="checkbox"/>
Participant trial ID number:	<input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>

Following Randomisation

- Please fax a copy of the participant's signed consent form to the STOP-ACEi trial office (0121 415 9135). Remember to add the participant trial ID number to the top of the consent form before sending.
- Please give the participant the following documents:
 - A copy of the appropriate Participant Advice Letter for treatment continuation or discontinuation
 - A blank copy of the Participant Diary. This should be completed by the participant between trial visits and collected at each visit.
 - A copy of the signed Consent Form
 - A copy of the Participant Information Sheet
- Please send a copy of the appropriate GP letter for treatment continuation or discontinuation to the participant's GP.
- Please save a copy of the Confirmation of Randomisation e-mail in the participant's case notes and a copy in the local Site File.
- Please keep a copy of the Consent Form and Participant Information Sheet in the participant's case notes and file the original in the local Site File.
- Please ensure that the participant's details are listed with the participant trial ID number in the Participant Identification Log in the Site File.

Ethnicity Codes

31	White - English / Welsh / Scottish / Northern Irish / British
32	White - Irish
33	White - Gypsy or Irish Traveller
34	White - Any Other White background
35	Mixed / Multiple ethnic group - White and Black Caribbean
36	Mixed / Multiple ethnic group - White and Black African
37	Mixed / Multiple ethnic group - White and Asian
38	Mixed / Multiple ethnic group - Any Other Mixed / multiple ethnic background
39	Asian / Asian British – Indian
40	Asian / Asian British – Pakistani
41	Asian / Asian British – Bangladeshi
42	Asian / Asian British – Chinese
43	Asian / Asian British - Any other Asian background
44	Black / African / Caribbean / Black British – African
45	Black / African / Caribbean / Black British – Caribbean
46	Black / African / Caribbean / Black British – Any other Black / African / Caribbean background
47	Other ethnic group – Arab
48	Other ethnic group – Any other ethnic group
98	Any other
99	Not known/not provided